Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Shares Outstanding (Weighted Average) (2022 - 2025)

Historic Shares Outstanding (Weighted Average) for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $125.0 million.

  • Indivior Pharmaceuticals' Shares Outstanding (Weighted Average) rose 2976190466190.48% to $125.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.0 million, marking a year-over-year increase of 2976190466190.48%. This contributed to the annual value of $0.36 for FY2024, which is 769.23% down from last year.
  • According to the latest figures from Q3 2025, Indivior Pharmaceuticals' Shares Outstanding (Weighted Average) is $125.0 million, which was up 2976190466190.48% from $125.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Shares Outstanding (Weighted Average) ranged from a high of $139.0 million in Q4 2022 and a low of $0.32 during Q1 2023
  • For the 4-year period, Indivior Pharmaceuticals' Shares Outstanding (Weighted Average) averaged around $75.2 million, with its median value being $124.5 million (2025).
  • Over the last 5 years, Indivior Pharmaceuticals' Shares Outstanding (Weighted Average) had its largest YoY gain of 4249999990000.0% in 2024, and its largest YoY loss of 5714.29% in 2024.
  • Indivior Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $139.0 million in 2022, then dropped by 1.44% to $137.0 million in 2023, then fell by 3.65% to $132.0 million in 2024, then fell by 5.3% to $125.0 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $125.0 million for Q3 2025, versus $125.0 million for Q2 2025 and $124.0 million for Q1 2025.